The outcomes of the other three trials (First-SIGNAL, NEJ002, and WJTOG3405) [37,38,39] confirmed the IPASS results in EGFR-mutant NSCLC patients when comparing gefitinib with doublet chemotherapy as first-line therapy. Here, EGFR is linked to non-small cell lung carcinoma.